Gastrointestinal Cancer

Eileen M. O’Reilly, MD, speaks to the progress being made with immune therapies in pancreatic cancer.

Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in the treatment of patients with pancreatic cancer.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, recaps recent second-line advancements in hepatocellular carcinoma.

Atezolizumab alone or in combination with cobimetinib failed to show superior overall survival compared with regorafenib for patients with chemorefractory metastatic colorectal cancer.

TAS-102 (trifluridine/tipiracil; Lonsurf) provided a 31% reduction in the risk of death compared with placebo in patients with heavily pretreated metastatic or advanced gastric cancer.

Second-line treatment with pembrolizumab (Keytruda) did not significantly improve overall survival or progression-free survival in patients with advanced or metastatic gastric or gastroesophageal junction cancer with a PD-L1 combined positive score ≥1.

George P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.

George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, senior vice president, Experimental Therapeutics, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses the use of larotrectinib in patients with TRK-fusion gastrointestinal (GI) cancers.

Thierry Conroy, MD, discusses the PRODIGE 24/CCTG PA.6 trial and shares his insight on future research with this treatment regimen.

TAS-120 demonstrated a clinically meaningful benefit with a manageable toxicity profile in patients with cholangiocarcinoma harboring FGFR2 gene fusions, including patients who had progressed on an FGFR inhibitor.

Selective internal radiation therapy in combination with sorafenib (Nexavar) did not provide a significant survival improvement compared with sorafenib alone in patients with advanced hepatocellular carcinoma.

Treatment with second-line ramucirumab improved median overall survival by 3.1 months compared with placebo in patients with advanced hepatocellular carcinoma with alpha-fetoprotein levels ≥400 ng/ml.

Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses survival data with modified FOLFIRINOX in pancreatic cancer.

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the pooled analysis of the REACH and REACH-2 studies in patients with hepatocellular carcinoma.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of immunotherapy in patients with microsatellite stable colorectal cancer.

Diane Reidy-Lagunes, MD, outlines the current state-of-the-art gastrointestinal care.

Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.

There are pivotal developments in colorectal cancer that have shaped the National Comprehensive Cancer Network guidelines in the past several years.

Although testing for some genetic defects has been incorporated into the treatment paradigm, the clinical utility of up-front tumor sequencing that would yield wide-ranging information has not yet been established.